Milestone Scores First Ex-US Approval: China Clears Etripamil Nasal Spray for PSVT

What happened

Milestone Pharmaceuticals announced that China's NMPA approved etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT), marking the first regulatory approval outside the United States. Everest Medicines will lead commercialization in Greater China, targeting an estimated 3-6 million Chinese patients with PSVT. This approval adds a second geographic market but does not immediately alter the company's near-term financial trajectory, as Everest handles sales and Milestone's revenue will likely come via milestones and royalties over time. The master report had not explicitly counted China as a near-term catalyst, focusing instead on US launch execution, AFib-RVR enrollment, and a European decision in 2027. While the news validates the molecule and expands the total addressable market, the economic contribution from China remains opaque without disclosure of partnership terms, and the US launch challenges—low net product revenue, heavy gross-to-net deductions, and unproven repeat prescribing—persist as the dominant value drivers.

Implication

First, the NMPA approval de-risks the regulatory path outside the US and provides a second revenue stream, but Everest Medicines controls commercialization, meaning Milestone's near-term cash benefit may be limited to small milestone payments. Second, the Chinese market is large by patient count but typically commands lower pricing than the US, and without disclosed royalty rates or upfront payments, the financial impact cannot be quantified reliably. Third, Milestone's existing RTW royalty burden applies only to US net sales, so China-derived royalties are not diluted by that obligation—a minor positive if China sales materialize meaningfully. Fourth, the approval does nothing to fix the US launch problem: Q2 product revenue was just $0.6 million despite >1,500 scripts, and the next two quarterly filings remain the critical test for revenue conversion and ATM usage. Fifth, investors should discount the headline and wait for concrete evidence of China launch traction or a material improvement in US net sales before upgrading the thesis; speculative approval headlines often fade without commercial execution.

Thesis delta

The original thesis centered on US CARDAMYST commercialization and AFib-RVR development, with Europe as the primary ex-US catalyst; China was not a major component. This approval adds a new upside option but does not change the near-term WAIT rating because US monetization and pipeline milestones still dominate value. The shift is positive but incremental, as the partnership with Everest defers Milestone's direct economic benefit and lacks disclosed terms to assess magnitude.